Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02806219 · ClinicalTrials.gov registry record · Phase 1
Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects
A Phase 1 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT02806219 is a Phase 1 study that has completed, run by UCB Biosciences. The registered enrollment target is 100 participants.
The verdict
NCT02806219, a Phase 1 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a single center, open-label, Phase 1 bioequivalence (BE) study in healthy subjects designed to demonstrate the bioequivalence of a single dose of certolizumab pegol (CZP) 200mg when injected by means of a prefilled syringe (PFS, reference) or injected by means of a injection device (e-Device, test).
Interventions
- DEVICE Prefilled syringe (PFS)
- DEVICE e-Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02806219
The ClinicalTrials.gov registry entry for NCT02806219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prefilled syringe (PFS) is the first listed.
NCT02806219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02806219 about?
NCT02806219 is a clinical study titled "Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects". This is a single center, open-label, Phase 1 bioequivalence (BE) study in healthy subjects designed to demonstrate the bioequivalence of a single dose of certolizumab pegol (CZP) 200mg when injected by means of a prefilled syringe (PFS, reference) or injected by means of a injection device (e-Device...
What is the current status of trial NCT02806219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02806219?
The interventions under investigation include: Prefilled syringe (PFS) (DEVICE), e-Device (DEVICE).
Who is sponsoring clinical trial NCT02806219?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.